Dendreon Raises $356 Million for Manufacturing, Marketing of Prostate Cancer Drug

Xconomy Seattle — 

Dendreon has just nailed down one of the biggest biotech financings in the U.S. this year. The Seattle-based biotech company (NASDAQ: DNDN) has secured $356 million for its quest to market the first treatment in the U.S. designed to actively stimulate the immune system to fight cancer cells like a virus.

The company sold 15 million shares at $24.75 apiece in an offering underwritten by JP Morgan Securities and Deutsche Bank. The price represents a 7 percent discount for investors from $26.64, the final market price on Tuesday before Dendreon announced its plan to sell new shares. The underwriters are also getting the option to buy another 2.25 million shares at the same price, which could bring in another $55.7 million.

After paying expenses, Dendreon expects to net $356 million from the offering, and possibly $409 million if the underwriters exercise all their options. Besides JP Morgan and Deutsche Bank, the offering was co-managed by Citigroup Global Markets, Morgan Stanley, Lazard Capital Markets, Leerink Swann, and Needham & Co.

This is the second major financing of the year for Dendreon, bringing its grand total of fundraising to $577 million. The company raised $221 million from investors back in May, just a few weeks after it shocked the cancer research and investment worlds by reporting that its immune-booster, sipuleucel-T (Provenge) was able to help men live longer with terminal prostate cancer. The company has filed for FDA clearance to start selling Provenge, as its first-ever marketed product after 17 years in existence. The agency has a deadline of May 1 to complete its review. If approved, the Dendreon treatment could eventually exceed $1 billion in sales, analysts say. About 30,000 men in the U.S. die of prostate cancer each year.

Snagging this much money greatly strengthens the balance sheet, and bargaining position, for CEO Mitchell Gold. Back in June, he told me that Dendreon envisions itself emerging as the next great anchor tenant for Seattle biotech, like Immunex once was in the 1990s, or like Biogen Idec is for Boston.

Mitchell Gold

Mitchell Gold

I don’t have a comprehensive list of the biggest financings of the year in biotech, but this has to rank pretty high. Cambridge, MA-based Vertex Pharmaceuticals (NASDAQ: VRTX) just raised $500 million in a stock offering this month to support its drugs in development for hepatitis C and cystic fibrosis. Rockville, MD-based Human Genome Sciences (NASDAQ: HGSI) also snapped up $456 million, after expenses, from investors who want a piece of its experimental drug for lupus, an autoimmune disease.

What will Dendreon do with all the loot? Dendreon plans to use the cash to build up manufacturing capacity at its initial site in Morris Plains, NJ, and at additional factories near Atlanta, GA, and in Orange County, CA. The company has gone on a hiring binge to get additional expertise in drug manufacturing, quality control and assurance, and marketing—things that it didn’t need a lot of when it was only an R&D shop. The company says it plans to double in size to about 600 employees.

Those people will be charged with a daunting manufacturing task. Dendreon said earlier this year that its initial plant in New Jersey only had enough capacity to meet demand for $500 million to $1 billion worth of drug per year. And manufacturing enough to meet demand is critical if Dendreon is going to successfully commercialize the new treatment.

Doing everything right in manufacturing is important for Dendreon, because Provenge isn’t made like a standard pill in a bottle, or liquid in a vial. It is composed of a genetically engineered protein found on prostate cancer cells, called PAP, fused to an immune-boosting compound, called GM-CSF. This fusion protein is incubated for a couple of days with an individual patient’s own white blood cells to “teach” them to fight prostate cancer. The revved-up cells are personalized to each patient, and need to be shipped back to the clinic to be re-infused into the patient.

So if there’s ever a major snowstorm in New Jersey, an earthquake in California, or a simple mix-up anywhere, it’s important that Dendreon have some extra capacity in the system to pick up the slack so patients aren’t left in the lurch, waiting for vital infusions of their precious cells. Dendreon doesn’t plan to have a big sugar daddy to help it do the heavy lifting in the U.S., because it has said it plans to commercialize the drug on its own here. The company is, however, looking for a partner to help develop and market Provenge overseas.

By posting a comment, you agree to our terms and conditions.

8 responses to “Dendreon Raises $356 Million for Manufacturing, Marketing of Prostate Cancer Drug”

  1. Brad LoncarBrad L says:

    Nice article on Dendreon. I appreciate the depth with which you cover the company.

    As a shareholder who is pretty angry about this offering, I’d like to know why for the last 6 months they said they’d raise the additional funding in a non-dilutive fashion, and now here they go and dilute the heck out of us.

  2. John says:

    Thx for sharing your thoughts!

    How does this strengthen their bargining position?

  3. Brad–thanks for the comment. Dilution is always a consideration with deals like this, but usually a short-term worry if the company has a good strategic plan. I would submit that it’s a much a bigger concern if a company doesn’t have enough money to really kick butt on its strategic plan, or if it has to cut corners. For example, if Dendreon fails to meet all the demand from prostate cancer patients when this drug is approved, because it had to pinch pennies now in Georgia or SoCal, I would bet the stock would take a far greater hit than whatever ding it’s getting this week from dilution.

    John–getting this much money on the balance sheet will absolutely strengthen Gold’s hand when he sits down with prospective partners who want ex-US rights to Provenge. He can continue to move full throttle on infrastructure buildout, and hiring plans, without having to accept whatever terms a Big Pharma wants to give him. That’s bargaining from a position of strength, and whoever he’s talking to on the other side of the table would surely know that, and have to raise their offer accordingly.

  4. John says:


    Makes sense… Appreciate the response.

  5. Paladin says:

    Thanks, Luke, for your continuing coverage of Dendreon. The good news about Provenge is spreading fast.

    As you’ve pointed out, with DNDN ramping up for full production and the recent BOD appointments and brilliant new COO hire, the future is looking brighter for prostate cancer patients who, hopefully, can hang on for the long-overdue FDA approval.

  6. Mitchell Gold……….Congratulations. This is a fantastic move. Once again, screw the critics, you’ve proven them wrong time and time again. Keep it up baby.

  7. c says:

    does all that money mean fda approval on 5-1-2010?